Psychedelic substances have been used historically for spiritual and mystical experiences, and recent interest focuses on their potential to treat chronic pain. Clinical trials support psychedelics' effectiveness for psychiatric conditions, but studies on chronic pain—such as cancer pain, phantom limb pain, migraine, and cluster headache—are few and mostly uncontrolled. Risks are relatively rare with careful patient screening and supervision. Key challenges include identifying mechanisms of action, selecting appropriate pain conditions, designing rigorous trials with proper control groups, minimizing unblinding bias, and accounting for patient mindset and setting. Evidence-based recommendations are needed for future research to yield informative results.
Psychedelic drugs that activate 5-HT2A receptors are known for treating psychiatric disorders, but growing evidence shows they also modulate immune responses by inhibiting pro-inflammatory cytokine release. In vivo studies demonstrate that psychedelics like (R)-DOI reduce inflammation in animal models of asthma and other inflammatory diseases. Clinical studies with psilocybin show effects on circulating cytokine levels, supporting translation from animal models to humans. These findings highlight the promise of targeting inflammation therapeutically. Recent research has identified compounds that maintain therapeutic potential without causing psychedelic effects, termed PIPI drugs (Psychedelic drug Informed but Psychedelic experience Inactive), offering new avenues for treating mental health and inflammation.